Bayer partners with NextRNA on lncRNA-targeted small molecules for cancer

Bayer entered a collaboration with NextRNA to develop two small molecules for cancer that work by targeting the interaction between disease-driving long non-coding RNAs (lncRNAs) and RNA-binding proteins, providing a point of validation for lncRNAs as a novel class of oncology targets.